Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
TERN

TERN - Terns Pharmaceuticals, Inc. Stock Price, Fair Value and News

$34.28-0.81 (-2.31%)
Market Closed

12/100

TERN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

12/100

TERN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$27.46

Target 3M

$30.9

Target 6M

$29.18

TERN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TERN Price Action

Last 7 days

-6.5%

Last 30 days

-17.4%

Last 90 days

320.1%

Trailing 12 Months

668.6%

TERN RSI Chart

TERN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TERN Valuation

Market Cap

3.1B

Price/Earnings (Trailing)

-32.7

Price/Sales (Trailing)

233.55

EV/EBITDA

-31.23

Price/Free Cashflow

-39.75

TERN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$27.46

Target 3M

$30.9

Target 6M

$29.18

TERN Fundamentals

TERN Revenue

Revenue (TTM)

13.2M

Rev. Growth (Yr)

1.72%

Rev. Growth (Qtr)

-6.24%

TERN Earnings

Earnings (TTM)

-94.4M

Earnings Growth (Yr)

-12.26%

Earnings Growth (Qtr)

-2.25%

TERN Profitability

EBT Margin

-712.43%

Return on Equity

-33.24%

Return on Assets

-31.31%

Free Cashflow Yield

-2.52%

TERN Investor Care

Shares Dilution (1Y)

6.05%

Diluted EPS (TTM)

-1.02

TERN Alerts

  • 1 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202512.8M13.0M13.2M0
202412.9M12.8M12.8M0
20234.7M7.9M012.9M
2022228.0K387.0K837.0K2.1M
20210118.0K117.0K170.0K
20200000
Get all data in R, Python etc through our Historical Stock Data APIs

About Terns Pharmaceuticals, Inc.

TERN
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of oncology, non-alcoholic steatohepatitis (NASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in clinical development for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
 WEBSITEternspharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES46

Terns Pharmaceuticals, Inc. Frequently Asked Questions

TERN is the stock ticker symbol of Terns Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Terns Pharmaceuticals, Inc. is 3.09 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check TERN's fair value in chart for subscribers.

The fair value guage provides a quick view whether TERN is over valued or under valued. Whether Terns Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Terns Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TERN.

As of Wed Jan 28 2026, TERN's PE ratio (Price to Earnings) is -32.7 and Price to Sales (PS) ratio is 233.55. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TERN PE ratio will change depending on the future growth rate expectations of investors.